Farallon Capital Management LLC Sells 3,245,000 Shares of Lantheus Holdings, Inc. $LNTH

Farallon Capital Management LLC cut its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 48.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,477,227 shares of the medical equipment provider’s stock after selling 3,245,000 shares during the quarter. Farallon Capital Management LLC owned about 5.24% of Lantheus worth $178,347,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Assenagon Asset Management S.A. bought a new position in Lantheus during the third quarter worth $65,654,000. Polaris Capital Management LLC bought a new stake in Lantheus in the 3rd quarter valued at $32,687,000. Norges Bank acquired a new stake in Lantheus in the 2nd quarter worth $32,631,000. Hotchkis & Wiley Capital Management LLC acquired a new stake in Lantheus in the 3rd quarter worth $11,443,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Lantheus by 73.4% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 448,452 shares of the medical equipment provider’s stock worth $23,001,000 after purchasing an additional 189,814 shares during the period. 99.06% of the stock is owned by institutional investors.

Lantheus Price Performance

NASDAQ:LNTH opened at $79.49 on Monday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.51 and a current ratio of 2.70. The company has a 50-day moving average of $70.53 and a 200-day moving average of $61.82. Lantheus Holdings, Inc. has a 52 week low of $47.25 and a 52 week high of $108.91. The company has a market capitalization of $5.17 billion, a price-to-earnings ratio of 23.59 and a beta of -0.11.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Thursday, February 26th. The medical equipment provider reported $1.67 earnings per share for the quarter, beating analysts’ consensus estimates of $1.17 by $0.50. Lantheus had a net margin of 15.15% and a return on equity of 30.77%. The business had revenue of $406.79 million for the quarter, compared to analysts’ expectations of $367.03 million. During the same quarter in the previous year, the firm posted $1.59 earnings per share. The firm’s revenue for the quarter was up 4.0% on a year-over-year basis. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, equities research analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. Mizuho upped their price objective on shares of Lantheus from $72.00 to $85.00 and gave the company an “outperform” rating in a research report on Friday, February 27th. Citizens Jmp lifted their target price on Lantheus from $73.00 to $78.00 and gave the stock a “market outperform” rating in a research report on Tuesday, February 24th. William Blair upgraded Lantheus from a “market perform” rating to an “outperform” rating in a research note on Thursday, February 26th. JonesTrading cut Lantheus from a “buy” rating to a “hold” rating in a report on Friday, February 27th. Finally, Truist Financial raised their price objective on Lantheus from $82.00 to $89.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. Seven analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $82.17.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.